Overview

A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19

Status:
Recruiting

Trial end date:
2021-04-23

Target enrollment:

Participant gender:

Summary

The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison with SOC alone in hospitalized COVID-19 patients.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Thirty Respiratory Limited

Treatments:

Nitric Oxide